AI driven optimization GeminiBio has launched aiMOS, an AI-enabled media optimization service for cell therapy manufacturing, developed with Tolemy Bio. This presents a sales opportunity to position advanced AI-driven media solutions to customers seeking faster development timelines and improved culture performance.

Custom media growth The company specializes in cGMP bioprocess liquids and custom supplements, leveraging multi-omics data. This creates cross-sell potential for clients needing tailored media or supplements to optimize specific cell lines or therapeutic modalities.

AO and AOF capacity GeminiBio operates two segregated facilities for animal-origin and animal-origin-free manufacturing, signaling reliability and compliance for diverse customer requirements. This can be leveraged to target customers with strict sourcing standards or regulatory needs.

Expansion footprint Recent facility expansions and ongoing enhancements of the manufacturing footprint indicate capacity for increased volume and new product lines. This supports upsell opportunities in larger production runs or accelerated timelines for growing programs.

Bioprocess ecosystem With ISO 13485 certification, FDA registered Class 1 Medical Device status, and a tech stack that spans iCIMS to Salesforce, GeminiBio presents a mature, compliant supply partner. This aligns with customers seeking dependable, quality-focused procurement and scalable digital collaboration.